Atorvastatin Industry, March 2015 Market Reports from Top Publishers

You might be interested in: drug, hypertension, acute coronary syndrome, angina, angina pectoris.


 
1-10 of 14 reports for Atorvastatin

Krebs Biochemicals & Industries Ltd (Symbol:524518 ) SWOT Analysis, Strategy, Revenues and Profits

Krebs Biochemicals & Industries Ltd (Symbol:524518 ) SWOT Analysis, Strategy, Revenues and Profits

  • $ 300
  • Company report
  • January 2015
  • by Global Data

This report is systematically updated by our analysts for each new purchase. This is to ensure that you get the latest information available on the company. The report will be updated and sent to you in ...

Kopran Limited (KOPRAN) - Financial and Strategic SWOT Analysis Review

Kopran Limited (KOPRAN) - Financial and Strategic SWOT Analysis Review

  • $ 300
  • Company report
  • January 2015
  • by Global Data

Summary Kopran Limited (Kopran) is an integrated pharmaceutical company. It is a group company of Parijat Enterprises. The company manufactures both active pharmaceutical ingredients (APIs) and finished ...

Atorvastatin  - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries)

Atorvastatin - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries)

  • $ 653
  • Industry report
  • January 2015
  • by Ark Patent Intelligence

Need fast access to comprehensive SPC, data exclusivity, and litigation intelligence that's simple to access and use? Already used by big pharma, biologics manufacturers and their law firms, Patent, Extension ...

Amlodipine, Atorvastatin  - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries)

Amlodipine, Atorvastatin - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries)

  • $ 653
  • Industry report
  • January 2015
  • by Ark Patent Intelligence

Need fast access to comprehensive SPC, data exclusivity, and litigation intelligence that's simple to access and use? Already used by big pharma, biologics manufacturers and their law firms, Patent, Extension ...

Atorvastatin, Ezetimibe  - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries)

Atorvastatin, Ezetimibe - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries)

  • $ 653
  • Industry report
  • January 2015
  • by Ark Patent Intelligence

Need fast access to comprehensive SPC, data exclusivity, and litigation intelligence that's simple to access and use? Already used by big pharma, biologics manufacturers and their law firms, Patent, Extension ...

Indoco Remedies Limited (INDOCO) - Financial and Strategic SWOT Analysis Review

Indoco Remedies Limited (INDOCO) - Financial and Strategic SWOT Analysis Review

  • $ 300
  • Company report
  • November 2014
  • by Global Data

Summary Indoco Remedies Limited (Indoco Remedies) is a pharmaceutical company. The company manufactures and markets formulations and active pharmaceutical ingredients. It offers products in the fields ...

Arch Pharmalabs Ltd. - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Arch Pharmalabs Ltd. - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • $ 250
  • Company report
  • November 2014
  • by Global Data

Summary Arch Pharmalabs Ltd. (Arch Pharmalabs) is a pharmaceutical company. The company manufactures and sells active pharmaceutical ingredients and intermediates to generic pharmaceutical players in domestic ...

Atorvastatin  - Comprehensive patent search

Atorvastatin - Comprehensive patent search

  • $ 8 160
  • Company report
  • October 2014
  • by Ark Patent Intelligence

Imagine having your own team of pharmaceutical patent experts at the click of a button. Used by the world's leading pharmaceutical companies and legal teams for over 10 years, Ark In-depth Searches are ...

PharmaPoint: Acute Coronary Syndrome - Japan Drug Forecast and Market Analysis to 2023

PharmaPoint: Acute Coronary Syndrome - Japan Drug Forecast and Market Analysis to 2023

  • $ 4 995
  • Industry report
  • July 2014
  • by Global Data

PharmaPoint: Acute Coronary Syndrome - Japan Drug Forecast and Market Analysis to 2023 Summary GlobalData estimates that the total market size for the 7MM in 2013 was $12.3bn, comprised of $5.0bn in branded ...

Kopran Limited (KOPRAN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Kopran Limited (KOPRAN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • $ 250
  • Company report
  • July 2014
  • by Global Data

Summary Kopran Limited (Kopran) is an integrated pharmaceutical company. It is a group company of Parijat Enterprises. The company manufactures both active pharmaceutical ingredients (APIs) and finished ...

About 400 reports for Atorvastatin

Download Unlimited Documents from Trusted Public Sources

Krka Annual Report 2013

  • January 2013
    216 pages
  • Drug And Medica  

  • Europe  

    Slovenia  

View report >

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.